Pcd Mutant Mice Research Articles

P400 protein characteristic to Purkinje cells and related proteins in cerebella from neuropathological mutant mice: autoradiographic study by 14C-leucine and phosphorylation.

P400 protein has been found in the cerebellum and localizes to Purkinje cells. It is a glycoprotein and reacts with plant lectins. Autoradiographic patterns of the protein profiles of mutant mice cerebella after intracranial injections of 14C-leucine were analyzed. P400 protein was one of the dominant proteins labeled in the control cerebellum. No incorporation of 14C-leucine to the position of P400 protein was found in the nervous and pcd mutant mice where no Purkinje cells and no P400 protein are present. P400 protein in weaver cerebellum was labelled more intensely than that in the control. In the staggerer mice, where dendritic arborization of Purkinje cell is poor and no spines are formed on the dendrites, no P400 protein was found and no 14C-leucine incorporation was observed to the position of P400 protein, suggesting that staggerer is a mutation where no P400 protein accumulated in the fractions being studied. P400 protein was phosphorylated independently of the presence of Ca2+. Among the proteins of the isolated Purkinje cells, P400 protein was one of the major proteins phosphorylated.

Loss of Purkinje cell-associated benzodiazepine receptors spares a high affinity subpopulation: a study with pcd mutant mice.

In order to identify the relative number of benzodiazepine (BZ) receptors in Purkinje and granule cells, the Purkinje cell degeneration (pcd) mutant mouse was used at different ages. In these mice, Purkinje cells have degenerated almost completely by 45-50 days of age. Granule cell loss occurs only later, and is most severe between 180 and 300 days. [3H]Flunitrazepam (FNZ) and [3H]ethyl-carboline-3-carboxylate (beta-CC) were used as ligands. In the 45-50-day-old pcd mice, it was found that there is approximately a 50% decrease in the number of receptors as labeled by [3H]beta-CC or [3H]FNZ, when the binding is expressed as fmol/cerebellum. The binding decreased by approximately 80% in 300-day-old pcd mice (fmol/cerebellum). [3H]FNZ was not displaced by 1 microM RO5-4864, ruling out binding to glial cells. Nonlinear regression analysis of FNZ saturation data provided evidence for two populations of receptors (high and low affinity sites). Only the low-affinity sites were reduced in number at 45 days. [3H]beta-CC saturation data showed, however, only one population of receptors. The total number of receptors (Bmax) was significantly lower for beta-CC than for FNZ in the control mice. It appears that 50% of the total BZ receptors is associated with Purkinje cells. In addition, our data on 300-day-old pcd mutants strongly suggest the existence of granule cell-associated BZ receptors.

Purkinje cell loss and the noradrenergic system in the cerebellum of pcd mutant mice

Purkinje cells in the cerebellum receive inhibitory noradrenergic input from the locus coeruleus. In pcd mutant mice all Purkinje cells degenerate by 45 days of age. The purpose of the present studies was to determine if the loss of these cerebellar neurons affects the amounts of norepinephrine in the cerebellum of mice 25–280 days of age. No significant changes in norepinephrine content were detected during or after Purkinje cell degeneration. However, since degeneration led to a reduction in cerebellar weight, the norepinephrine concentration was increased in pcd mutants. These results indicate that despite the loss of a major postsynaptic target (Purkinje cells), the cerebellar noradrenergic input remains stable.

Exaggerated cyclic AMP accumulation and glial cell reaction in the cerebellum during Purkinje cell degeneration in pcd mutant mice.

The Purkinje cell degeneration mutant (pcd) is characterized by a complete loss of cerebellar Purkinje cells. Norepinephrine causes an accumulation of cyclic AMP in the cerebellum of pcd that is far greater than in normal mice. Experiments were conducted 1) to correlated changes in the cyclic-nucleotide response with a histologic examination of the cerebellum during neuronal loss and 2) to examine the role of cyclic AMP catabolism and adenosine receptor interactions in the phenomenon. The greatest elevation in cyclic AMP occurred between 30 and 128 days of age when a severe astrocytic response was demonstrated throughout the cerebellar cortex. Purkinje cells had degenerated by 45 days of age. Norepinephrine elicited a smaller increase in cyclic AMP from 155-day-old mice than at earlier ages, and the response continued to decrease with age; at 270 days, equal accumulation, and at 365 days. lower accumulation of cyclic AMP was detected in pcd cerebella. During this time, the Purkinje cell debris had been removed, the granule cell layer was depleted of granule cells, and the molecular layer was deprived of a large number of parallel fibers. However, although phagocytosis of neuronal debris was completed, large numbers of astrocytic processes were still seen in the neuropil. Biochemical experiments in vitro established that the exaggerated accumulation of cyclic AMP in the presence of norepinephrine was not due to lower catabolism of cyclic AMP, a synergistic interaction with adenosine, or a result of lower protein in the pcd cerebellum. The correlates of heightened norepinephrine-stimulated accumulation of cyclic AMP with neuronal loss and the glial cell reaction might indicate that cyclic nucleotides play a role in controlling some glial cell functions, ie, proliferation, migration, and phagocytosis.

Exaggerated norepinephrine-stimulated accumulation of cyclic AMP in vitro in cerebellar slices from pcd mutant mice following Purkinje cell loss.

Norepinephrine caused in vitro an accumulation of cylic AMP in slices of the cerebellum from pcd mice which was 300 percent greater than in cerebella from age-matched, heterozygous, normal mice. Purkinje cells had disappeared in the pcd mice at the time when the exaggerated hormonal response was seen. The data indicate that high cyclic AMP accumulation can take place in cerebellar cells other than Purkinje cells.